Dr. Nancy A. Simonian M.D.Syros Pharmaceuticals
Nancy is the founding CEO of Syros and has an established track record of value creation in biotechnology. Prior to Syros, she was Chief Medical Officer at Millennium Pharmaceuticals, and previously Vice President of Clincal Development at Biogen. Nancy has overseen the successful development of numerous medicines. Under Nancy’s leadership as Chief Medical Officer at Millennium, VELCADE became a mainstay of treatment for multiple myeloma. Nancy led development of Millennium’s clinical pipeline, include NINLARO for hematologic malignancies and ENTYVIO for inflammatory bowel disease. At Biogen, Nancy played a central role in developing AVONEX and TYSABRI for multiple sclerosis. Nancy started her career as an assistant professor at Harvard Medical School and neurology staff at Massachusetts General Hospital (MGH).
Year appointed: 2012